



**VIJAYA**<sup>®</sup>  
**DIAGNOSTIC**  
**CENTRE**

May 07, 2026

To  
The Listing Department,  
**National Stock Exchange of India Limited**  
NSE Symbol: **VIJAYA**

To  
The Corporate Relations Department,  
**BSE Limited**  
BSE Scrip Code: **543350**

Dear Sir/Madam,

**Subject: Outcome of the Board Meeting held on Thursday, May 07, 2026 - Audited Financial Results for the quarter and year ended March 31, 2026**

**Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") as amended from time to time.**

We hereby inform you that, the Board of Directors at their meeting held today i.e., on **Thursday, May 07, 2026**, has inter-alia considered and approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.

In terms of the above, we enclose herewith the following:

- a. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, as per Indian Accounting Standards; and
- b. Audit Reports on the Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2026.

We confirm that the Statutory Auditors of the Company have issued Audit Reports with '**Unmodified Opinion**' on the Audited Financial Results of the Company (Standalone and Consolidated) for the year ended March 31, 2026.

The Board Meeting commenced at 05:00 P.M. and concluded at 06:45 P.M. (IST).

Kindly take the same on record.

Thanking You.

Yours Faithfully  
For **Vijaya Diagnostic Centre Limited**

**Ankit Shah**  
**Chief Financial Officer**

Encl.: As above



**VIJAYA  
DIAGNOSTIC  
CENTRE**

Vijaya Diagnostic Centre Limited  
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India  
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Standalone Financial Results for the quarter and year ended 31 March 2026

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended	
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		Audited (Refer Note 3)	Unaudited (Refer Note 7)	Audited (Refer Note 3 & 7)	Audited	Audited (Refer Note 7)
<b>1</b>	<b>Income</b>					
	(a) Revenue from operations	20,626.71	19,308.31	16,163.85	76,542.88	63,400.30
	(b) Other income	722.75	554.51	548.91	2,515.81	1,852.09
	<b>Total income</b>	<b>21,349.46</b>	<b>19,862.82</b>	<b>16,712.76</b>	<b>79,058.69</b>	<b>65,252.39</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	2,367.27	2,291.98	2,064.74	8,938.90	7,923.24
	(b) Employee benefits expense	3,137.70	3,065.11	2,626.05	12,139.49	10,383.38
	(c) Finance costs	874.11	795.23	660.04	3,081.54	2,499.24
	(d) Depreciation and amortisation expense	2,141.93	2,124.75	1,714.77	8,042.50	6,466.43
	(e) Other expenses	6,002.50	5,682.97	4,990.79	23,217.42	19,624.71
	<b>Total expenses</b>	<b>14,523.51</b>	<b>13,960.04</b>	<b>12,056.39</b>	<b>55,419.85</b>	<b>46,897.00</b>
<b>3</b>	<b>Profit before tax and exceptional items [1-2]</b>	<b>6,825.95</b>	<b>5,902.78</b>	<b>4,656.37</b>	<b>23,638.84</b>	<b>18,355.39</b>
<b>4</b>	<b>Exceptional items (Refer Note 5)</b>	-	-	102.96	-	102.96
<b>5</b>	<b>Profit before tax [3-4]</b>	<b>6,825.95</b>	<b>5,902.78</b>	<b>4,553.41</b>	<b>23,638.84</b>	<b>18,252.43</b>
<b>6</b>	<b>Tax expense</b>					
	(a) Current tax	1,472.17	1,155.00	940.23	5,014.17	3,892.56
	(b) Deferred tax	88.64	326.54	270.70	793.64	766.90
	<b>Total tax expense</b>	<b>1,560.81</b>	<b>1,481.54</b>	<b>1,210.93</b>	<b>5,807.81</b>	<b>4,659.46</b>
<b>7</b>	<b>Profit for the period/year [5 - 6]</b>	<b>5,265.14</b>	<b>4,421.24</b>	<b>3,342.48</b>	<b>17,831.03</b>	<b>13,592.97</b>
<b>8</b>	<b>Other comprehensive income</b>					
	<b>Items that will not be reclassified to profit or loss</b>					
	(a) Remeasurement of defined benefit liability / (asset)	56.93	(3.64)	(21.98)	83.21	(34.84)
	(b) Income-tax relating to above item	(14.33)	0.92	5.53	(20.94)	8.77
	<b>Other comprehensive income for the period/year (net of tax)</b>	<b>42.60</b>	<b>(2.72)</b>	<b>(16.45)</b>	<b>62.27</b>	<b>(26.07)</b>
<b>9</b>	<b>Total comprehensive income for the period/year [7 + 8]</b>	<b>5,307.74</b>	<b>4,418.52</b>	<b>3,326.03</b>	<b>17,893.30</b>	<b>13,566.90</b>
<b>10</b>	<b>Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6 &amp; 7)</b>	1,028.97	1,027.25	1,026.37	1,028.97	1,026.37
<b>11</b>	<b>Other equity (Refer Note 7)</b>				93,316.29	76,987.34
<b>12</b>	<b>Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 6 &amp; 7)</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualised)
	- Basic (in Rs.)	5.12	4.30	3.25	17.33	13.23
	- Diluted (in Rs.)	5.11	4.29	3.24	17.31	13.20

**Notes:**

1. The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on May 07, 2026. The above results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion on these results.

3. The standalone figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year-to-date standalone figures up to the third quarter of the respective financial years.

4. The Company has one reportable segment (viz. Diagnostic services) as per the requirements of Ind AS 108 "Operating Segments".
5. During the previous year, the Company had incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these were not incurred in the ordinary course of business of operations of the Company.
6. During the year ended 31 March 2026, the Company has issued 88,658 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.
7. The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation ("the Scheme") of its subsidiary, Medinova Diagnostic Services Limited ("Transferor Company"), with the Company with effect from 01 April 2024 ("the Appointed Date"), pursuant to Sections 230 to 232 of the Companies Act 2013 and other applicable provisions, and the rules made thereunder.
- The Scheme was sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), vide order dated 13 October 2025 and the certified copies of the order passed by NCLT has also been duly filed with the Registrar of Companies.
- Accordingly, the Company has accounted for the amalgamation as specified in the Scheme in accordance with the "pooling of interest" method as laid down in Appendix C- 'Business Combinations of Entities Under Common Control' of Ind AS 103, Business Combinations, notified under Section 133 of the Companies Act read with the Companies (Indian Accounting Standards) Rules, 2015 and all the comparatives presented have been restated to give effect of the amalgamation from the beginning of the previous year.
- In giving effect to the amalgamation:
- All the assets, liabilities, reserves and surplus as appearing in the transferor company have been transferred and vested in the Company.
  - In consideration for the above Scheme, the Company issued 171,792 shares amounting to INR 1,405 lakhs for 3,779,420 shares held by non controlling shareholders of the transferor company.
  - The difference between value of share capital of transferor company and existing investment in the transferor company plus the consideration paid as mentioned above has been transferred to 'Amalgamation Reserve' under 'Other Equity'.
- Further to the above, the Company, on 8 January 2026, allotted 171,792 equity shares of INR 1 each in exchange for 3,779,420 equity shares held by the non-controlling shareholders of the transferor company. The Company has received in-principle listing approvals from the respective stock exchanges for the listing of 171,792 equity shares and in the process of executing the corporate action with the depositories.
8. The Government of India has consolidated existing labour legislations into four comprehensive labour codes effective 21 November, 2025. These codes include Code on Wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). However, the final rules under these codes are yet to be notified. Pending notification, the Company has evaluated the incremental impact of these changes in accordance with the guidance issued by the Institute of Chartered Accountants of India and has estimated and recognised the additional gratuity and leave liability of Rs 78.82 lakhs basis the actuarial valuation. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide appropriate accounting effect on the basis of such developments as needed.
9. The Board of Directors at its meeting held on May 07, 2026, has proposed and recommended a dividend of Re. 2/- per equity share of Re. 1 each, i.e., 200% for the financial year 2025-26, subject to the approval of the members at the ensuing Annual General Meeting.
10. The results of the Company are available for investors at [www.vijayadiagnostic.com](http://www.vijayadiagnostic.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

Place: Hyderabad  
Date: 07 May 2026

*for and on behalf of the Board of Directors of*  
**Vijaya Diagnostic Centre Limited**

**SUPRITA**  
**SURA REDDY**  
Digitally signed by  
SUPRITA SURA  
REDDY  
Date: 2026.05.07  
18:18:32 +05'30'  
**S Suprita Reddy**  
Managing Director & CEO  
DIN Number: 00263618

Standalone Balance Sheet		(Rs. in Lakhs except as stated)	
Sl. No.	Particulars	As at	As at
		31 March 2026	31 March 2025
		Audited	Audited (Refer Note 7)
	<b>ASSETS</b>		
<b>I</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	51,565.59	41,852.76
	(b) Capital work-in-progress	3,424.01	6,717.83
	(c) Right-of-use assets	34,210.96	24,930.61
	(d) Other intangible assets	454.67	530.59
	(e) Intangible assets under development	78.65	-
	(e) Financial assets		
	(i) Investments	14,264.82	14,336.11
	(ii) Loans	2,709.00	1,626.00
	(iii) Other financial assets	4,579.79	1,446.03
	(f) Other tax assets (net)	-	116.15
	(g) Other non-current assets	3,082.22	864.00
	<b>Total non-current assets</b>	<b>114,369.71</b>	<b>92,420.08</b>
<b>II</b>	<b>Current assets</b>		
	(a) Inventories	445.71	386.38
	(b) Financial assets		
	(i) Investments	22,493.27	18,308.88
	(ii) Trade receivables	2,103.27	1,283.68
	(iii) Cash and cash equivalents	3,776.47	1,084.12
	(iv) Bank balances other than (iii) above	1,305.96	3,123.71
	(v) Other financial assets	801.05	4,902.72
	(c) Other current assets	680.02	587.96
	<b>Total current assets</b>	<b>31,605.75</b>	<b>29,677.45</b>
	<b>TOTAL ASSETS (I + II)</b>	<b>145,975.46</b>	<b>122,097.53</b>
	<b>EQUITY AND LIABILITIES</b>		
<b>I</b>	<b>Equity</b>		
	(a) Equity share capital	1,028.97	1,026.37
	(b) Other equity	93,316.29	76,987.34
	<b>Total equity</b>	<b>94,345.26</b>	<b>78,013.71</b>
<b>II</b>	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	(i) Lease liabilities	37,805.95	27,254.72
	(b) Provisions	1,051.52	943.71
	(c) Deferred tax liabilities (net)	1,325.90	511.31
	(d) Other non-current liabilities	46.60	30.14
	<b>Total non-current liabilities</b>	<b>40,229.97</b>	<b>28,739.88</b>
<b>III</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	(i) Lease liabilities	1,816.89	1,943.87
	(ii) Trade payables		
	- Total outstanding dues of micro enterprises and small enterprises; and	256.16	90.75
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	3,236.48	2,979.65
	(iii) Other financial liabilities	4,745.62	9,003.55
	(b) Other current liabilities	489.11	413.32
	(c) Provisions	764.57	558.71
	(d) Current tax liabilities (net)	91.40	354.09
	<b>Total current liabilities</b>	<b>11,400.23</b>	<b>15,343.94</b>
	<b>Total liabilities (II + III)</b>	<b>51,630.20</b>	<b>44,083.82</b>
	<b>TOTAL EQUITY AND LIABILITIES (I + II + III)</b>	<b>145,975.46</b>	<b>122,097.53</b>
		<p style="text-align: right;"><i>for and on behalf of the Board of Directors of</i>  <b>Vijaya Diagnostic Centre Limited</b>  SUPRITA  SURA  REDDY  Digitally signed by  SUPRITA SURA REDDY  Date: 2026.05.07  18:19:19 +05'30'</p> <p><b>S Suprita Reddy</b>  Managing Director &amp; CEO  DIN Number: 00263618</p>	
Place: Hyderabad Date: 07 May 2026			

Standalone Statement of Cash flows		(Rs. in Lakhs except as stated)	
	Particulars	For the period ended 31 March 2026	For the period ended 31 March 2025
(A)	<b>Cash flows from operating activities</b>	<b>Audited</b>	<b>Audited (Refer Note 7)</b>
	<b>Profit before tax</b>	<b>23,638.84</b>	<b>18,252.44</b>
	<i>Adjustments for:</i>		
	Depreciation and amortisation expense	8,042.50	6,466.44
	Net gain on sale/retirement of property, plant and equipment	(69.10)	28.81
	Interest income under the effective interest method	(727.01)	(609.07)
	Profit on sale of mutual fund investments (net)	(729.34)	(773.51)
	Fair value gain on investments measured at FVTPL	(437.92)	(409.69)
	Share of Profit from VDC Diagnostics (Karnataka) LLP	(435.72)	-
	Loss allowance for trade receivables	60.00	-
	Equity-settled share-based payment transactions (ESOP)	172.85	159.20
	Finance costs	2,905.84	2,290.80
	Liabilities no longer required written back	(5.29)	(31.44)
	<b>Operating profit before working capital adjustments</b>	<b>32,415.65</b>	<b>25,373.98</b>
	<i>Working capital adjustments:</i>		
	Decrease / (Increase) in trade receivables	(859.59)	30.43
	Decrease / (Increase) in inventories	(59.33)	64.37
	(Increase) in other financial assets	(16.26)	(108.38)
	(Increase) in other assets and deposits	(1,715.54)	(1,051.82)
	Increase in trade payables	427.53	5.11
	Increase in provisions and other liabilities	424.34	161.17
	Increase in other financial liabilities	140.35	93.78
	<b>Cash generated from operating activities</b>	<b>30,757.15</b>	<b>24,568.64</b>
	Income tax paid, net	(5,160.71)	(3,730.83)
	<b>Net cash generated from operating activities</b>	<b>25,596.44</b>	<b>20,837.81</b>
(B)	<b>Cash flows from investing activities</b>		
	Acquisition of property, plant and equipment, capital work-in-progress (CWIP), other intangible assets and intangible assets under development (including capital advances and capital creditors)	(16,581.53)	(7,349.36)
	Proceeds from sale of property, plant and equipment	128.68	212.54
	Investment in liquid mutual funds/bonds, net	(3,017.13)	(6,212.70)
	Deposits made having original maturity of more than 3 months	(5,026.13)	(8,485.00)
	Deposits redeemed having original maturity of more than 3 months	7,686.99	5,595.21
	Loans given to subsidiaries	(1,543.00)	(840.00)
	Loans repaid by subsidiaries	460.00	-
	Investment and Profit withdrawal from VDC LLP	507.01	-
	Interest received on deposits having original maturity of more than 3 months	596.45	223.72
	Interest received on loans given to subsidiaries	204.59	168.30
	<b>Net cash used in investing activities</b>	<b>(16,584.07)</b>	<b>(16,687.29)</b>
(C)	<b>Cash flows from financing activities</b>		
	Principal payment of lease liabilities	(1,744.52)	(1,839.59)
	Finance costs paid	(2,841.04)	(2,228.58)
	Proceeds from the exercise of employee stock options	319.89	410.42
	Dividend paid	(2,054.35)	(1,026.23)
	<b>Net cash used in financing activities</b>	<b>(6,320.02)</b>	<b>(4,683.98)</b>
	<b>Net increase/(decrease) in cash and cash equivalents (A + B + C)</b>	<b>2,692.35</b>	<b>(533.46)</b>
	Cash and cash equivalents at the beginning of the period	1,084.12	1,617.58
	<b>Cash and cash equivalents at the end of the period</b>	<b>3,776.47</b>	<b>1,084.12</b>
	Cash and cash equivalents as per above comprise of the following:		
	<b>Particulars</b>	<b>As at 31 March 2026</b>	<b>As at 31 March 2025</b>
	Cash on hand	71.84	100.38
	Balances in wallets	15.81	-
	Balances with banks		
	- in current accounts	1,174.80	482.74
	- in deposit accounts having maturity less than three months	2,514.02	501.00
	<b>Total cash and cash equivalents</b>	<b>3,776.47</b>	<b>1,084.12</b>
		<i>for and on behalf of the Board of Directors of</i> <b>Vijaya Diagnostic Centre Limited</b> <b>SUPRITA</b> <b>SURA REDDY</b> <small>Digitally signed by  SUPRITA SURA REDDY  Date: 2026.05.07  18:19:47 +05'30'</small> <b>S Suprita Reddy</b> Managing Director & CEO DIN Number: 00263618	
Place: Hyderabad Date: 07 May 2026			

## Independent Auditor's Report

### To the Members of Vijaya Diagnostic Centre Limited

### Report on the audit of the Standalone Annual Financial Results

#### Opinion

We have audited the accompanying standalone annual financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

#### Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively

## Independent Auditor's Report (Continued)

### Vijaya Diagnostic Centre Limited

for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Independent Auditor's Report (Continued)**  
**Vijaya Diagnostic Centre Limited**

**Other Matters**

- a. The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
- b. The Company has accounted for the amalgamation of Medinova Diagnostic Services Limited ("transferor company") with the Company during the year ended 31 March 2026 in accordance with the Scheme of Amalgamation approved by the National Company Law Tribunal (NCLT) vide order dated 13 October 2025. The Amalgamation has been accounted by the Company by restating the financial information in the financial statements in respect of prior periods as if it had occurred from the beginning of the preceding year as per the requirement of Indian Accounting Standards.

The corresponding figures for the year ended 31 March 2025, in so far it pertains to the transferor company, have been audited by another auditor who had expressed an unmodified opinion on 03 May 2025.

Our opinion is not modified in respect of this matter.

For **B S R and Co**

*Chartered Accountants*

Firm's Registration No.:128510W

**BALKISHA** Digitally signed by  
**N KABRA** BALKISHAN KABRA  
Date: 2026.05.07  
18:36:49 +05'30'

**Balkishan Kabra**

*Partner*

Hyderabad

07 May 2026

Membership No.: 221202

UDIN:26221202OTNMIB2730



**VIJAYA  
DIAGNOSTIC  
CENTRE**

Vijaya Diagnostic Centre Limited

CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India

Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

**Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026**

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended	
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		Audited (Refer Note 3)	Unaudited	Audited (Refer Note 3)	Audited	Audited (Refer Note 7)
<b>1</b>	<b>Income</b>					
	(a) Revenue from operations	21,937.67	20,521.03	17,324.25	81,420.19	68,139.01
	(b) Other income	240.03	510.19	554.86	2,079.92	1,831.95
	<b>Total income</b>	<b>22,177.70</b>	<b>21,031.22</b>	<b>17,879.11</b>	<b>83,500.11</b>	<b>69,970.96</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	2,492.73	2,402.51	2,216.52	9,468.44	8,476.35
	(b) Employee benefits expense	3,383.47	3,303.65	2,840.28	13,073.76	11,215.28
	(c) Finance costs	932.38	859.45	719.11	3,323.09	2,674.43
	(d) Depreciation and amortisation expense	2,432.84	2,433.89	1,882.14	9,182.44	7,059.74
	(e) Other expenses	6,509.46	6,209.44	5,381.04	25,184.49	21,125.79
	<b>Total expenses</b>	<b>15,750.88</b>	<b>15,208.94</b>	<b>13,039.09</b>	<b>60,232.22</b>	<b>50,551.59</b>
<b>3</b>	<b>Profit before tax and exceptional items [1 - 2]</b>	<b>6,426.82</b>	<b>5,822.28</b>	<b>4,840.02</b>	<b>23,267.89</b>	<b>19,419.37</b>
<b>4</b>	<b>Exceptional items (Refer Note 4)</b>	-	-	102.96	-	102.96
<b>5</b>	<b>Profit before tax [3 - 4]</b>	<b>6,426.82</b>	<b>5,822.28</b>	<b>4,737.06</b>	<b>23,267.89</b>	<b>19,316.41</b>
<b>6</b>	<b>Tax expense</b>					
	(a) Current tax	1,479.08	1,165.87	939.87	5,067.73	4,117.77
	(c) Deferred tax, net	154.81	338.88	310.72	902.50	819.29
	<b>Total tax expense</b>	<b>1,633.89</b>	<b>1,504.75</b>	<b>1,250.59</b>	<b>5,970.23</b>	<b>4,937.06</b>
<b>7</b>	<b>Profit for the period/year [5-6]</b>	<b>4,792.93</b>	<b>4,317.53</b>	<b>3,486.47</b>	<b>17,297.66</b>	<b>14,379.35</b>
<b>8</b>	<b>Other comprehensive income</b>					
	<b>Items that will not be reclassified to profit or loss</b>					
	(a) Remeasurement of defined benefit liability / (asset)	60.88	(3.91)	13.39	86.89	0.53
	(b) Income-tax relating to above item	(15.33)	0.99	(3.38)	(21.87)	(0.14)
	<b>Other comprehensive income for the period/year (net of tax)</b>	<b>45.55</b>	<b>(2.92)</b>	<b>10.01</b>	<b>65.02</b>	<b>0.39</b>
<b>9</b>	<b>Total comprehensive income for the period/year [7+8]</b>	<b>4,838.48</b>	<b>4,314.61</b>	<b>3,496.48</b>	<b>17,362.68</b>	<b>14,379.74</b>
<b>10</b>	<b>Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6 and 7)</b>	1,028.97	1,027.25	1,026.37	1,028.97	1,026.37
<b>11</b>	<b>Other equity (Refer Note 7)</b>				94,686.21	78,887.88
<b>12</b>	<b>Earnings per equity share (Face value of Re. 1 each fully paid up) (Refer Note 6 and 7)</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualised)
	- Basic (in Rs.)	4.66	4.20	3.39	16.81	13.99
	- Diluted (in Rs.)	4.65	4.19	3.38	16.79	13.97

**Notes:**

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).

2. The above consolidated financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on May 07, 2026. The above results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion on these results.

3. The consolidated figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year-to-date standalone figures up to the third quarter of the respective financial years.

4. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".

5. During the previous year, the Company had incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these were not incurred in the ordinary course of business of operations of the Company.

6. During the year ended 31 March 2026, the Company has issued 88,658 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.

7. The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation (“the Scheme”) of its subsidiary, Medinova Diagnostic Services Limited (“Transferor Company”), with the Company with effect from 01 April 2024 (“the Appointed Date”), pursuant to Sections 230 to 232 of the Companies Act 2013 and other applicable provisions, and the rules made thereunder.

The Scheme was sanctioned by the Hon’ble National Company Law Tribunal, Hyderabad Bench (“NCLT”), vide order dated 13 October 2025 and the certified copies of the order passed by NCLT has also been duly filed with the Registrar of Companies.

Accordingly, the Company has accounted for the amalgamation in standalone financial statements as specified in the Scheme in accordance with the “pooling of interest” method as laid down in Appendix C- ‘Business Combinations of Entities Under Common Control’ of Ind AS 103, Business Combinations, notified under Section 133 of the Companies Act read with the Companies (Indian Accounting Standards) Rules, 2015 and all the comparatives presented have been restated to give effect of the amalgamation from the beginning of the previous year.

In giving effect to the amalgamation:

a. All the assets, liabilities, reserves and surplus as appearing in the transferor company have been transferred and vested in the Company.

b. In consideration for the above Scheme, the Company issued 171,792 shares amounting to INR 1,405 lakhs for 3,779,420 shares held by non controlling shareholders of the transferor company.

c. The difference between value of non controlling interest and the consideration paid as mentioned above has been adjusted to ‘Retained earnings’ under ‘Other Equity’.

Further to the above, the Company, on 8 January 2026, allotted 171,792 equity shares of INR 1 each in exchange for 3,779,420 equity shares held by the non-controlling shareholders of the transferor company. The Company has received in-principle listing approvals from the respective stock exchanges for the listing of 171,792 equity shares and in the process of executing the corporate action with the depositories.

8. The Government of India has consolidated existing labour legislations into four comprehensive labour codes effective 21 November, 2025. These codes include Code on Wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). However, the final rules under these codes are yet to be notified. Pending notification, the Group has evaluated the incremental impact of these changes in accordance with the guidance issued by the Institute of Chartered Accountants of India and has estimated and recognised the additional gratuity and leave liability of Rs 91.83 lakhs basis the actuarial valuation. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide appropriate accounting effect on the basis of such developments as needed.

9. The Board of Directors at its meeting held on May 07, 2026, has proposed and recommended a dividend of Re. 2/- per equity share of Re. 1 each, i.e., 200% for the financial year 2025–26, subject to the approval of the members at the ensuing Annual General Meeting.

10. The results of the Group are available for investors at [www.vijayadiagnostic.com](http://www.vijayadiagnostic.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

*for and on behalf of the Board of Directors of*

**Vijaya Diagnostic Centre Limited**

**SUPRITA**  
**SURA**  
**REDDY**

Digitally signed  
by SUPRITA SURA  
REDDY  
Date: 2026.05.07  
18:15:46 +05'30'

**S Suprita Reddy**

Managing Director & CEO

DIN Number: 00263618

Place: Hyderabad  
Date: 07 May 2026





## Independent Auditor's Report

### To the Board of Directors of Vijaya Diagnostic Centre Limited

### Report on the audit of the Consolidated Annual Financial Results

#### Opinion

We have audited the accompanying consolidated annual financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid consolidated annual financial results:

a. include the annual financial results of the following entities

1. Vijaya Diagnostic Centre Limited (**Parent**)

#### Subsidiaries

2. VDC Diagnostics (Karnataka) LLP
  3. Medinova Millennium MRI Services LLP
  4. P H Diagnostic Centre Private Limited
  5. Namrata Diagnostic Centre Private Limited (Struck off on 06 April 2024)
  6. Doctorslab Medical Services Private Limited (Struck off on 06 April 2024)
  7. Medinova Diagnostic Services Limited (Amalgamated with the Parent, effective from 1 April 2024)
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditors referred to in sub paragraph no. (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide

## Independent Auditor's Report (Continued)

### Vijaya Diagnostic Centre Limited

a basis for our opinion on the consolidated annual financial results.

#### Management's and Board of Directors'/Designated Partners' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies / Designated Partners of limited liability partnerships (LLP) included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company / LLP and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies / Designated Partners of limited liability partnerships (LLP) included in the Group are responsible for assessing the ability of each company / LLP to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors / designated partners either intends to liquidate the company / LLP or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies / Designated Partners of the LLP included in the Group is responsible for overseeing the financial reporting process of each company / LLP.

#### Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

## Independent Auditor's Report (Continued)

### Vijaya Diagnostic Centre Limited

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements of such entity included in the consolidated annual financial results of which we are the independent auditor. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

#### Other Matters

- a. The consolidated annual financial results include the audited financial results of three subsidiaries, whose financial statements reflects total assets (before consolidation adjustments) of Rs. 8,118.21 lakhs as at 31 March 2026, total revenue (before consolidation adjustments) of Rs. 5,002.51 lakhs and total net profit after tax (before consolidation adjustments) of Rs. 35.11 lakhs and net cash outflows (before consolidation adjustments) of Rs 4.24 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditor's reports on financial statements of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

- b. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which

B S R and Co

**Independent Auditor's Report (Continued)**  
**Vijaya Diagnostic Centre Limited**

were subject to limited review by us.

For **B S R and Co**

*Chartered Accountants*

Firm's Registration No.:128510W

**BALKISHA** Digitally signed by  
BALKISHAN KABRA  
**N KABRA** Date: 2026.05.07  
18:35:37 +05'30'

**Balkishan Kabra**

*Partner*

Hyderabad

07 May 2026

Membership No.: 221202

UDIN:26221202NSOTCF4468